Edmund Dunn is CAO at Monte Rosa Therapeutics, Inc. (GLUE). They have made 6 open-market trades across 1 company since 2024, most recently 2026-03-04.
CIK 0001989401
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GLUE | 22,554 | $244K |
Shares reported on the most recent Form 4, priced at the 2026-03-05 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GLUE | SELL | 2026-03-04 | 2026-03-05 | $17.96 | $2K | -6.6% | -1.4% | +2.3% |
| GLUE | SELL | 2026-02-27 | 2026-03-02 | $18.09 | $465K | -9.2% | -2.8% | +11.2% |
| GLUE | SELL | 2026-01-05 | 2026-01-05 | $15.17 | $16K | +69.9% | +37.8% | +19.5% |
| GLUE | SELL | 2025-06-03 | 2025-06-04 | $4.45 | $9K | +4.8% | +8.0% | +7.0% |
| GLUE | SELL | 2024-07-05 | 2024-07-09 | $3.83 | $6K | +7.3% | +0.3% | +27.7% |
| GLUE | SELL | 2024-06-03 | 2024-06-05 | $4.04 | $5K | -11.8% | -12.5% | +39.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.